Study: miRNA-7110 may be a promising drug target and biomarker for various diseases
Study: miRNA-7110 may be a promising drug target and biomarker for various diseases
MicroRNA 7110 (miRNA-7110) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.
miRNA-7110 is a part of the microRNA family, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. These molecules have been shown to regulate gene expression and are involved in a wide range of biological processes, including cell growth, differentiation, and apoptosis.
One of the key features of miRNA-7110 is its size and stability. It is approximately 200 nucleotides long and has a stability index of 21.83, which indicates that it is stable in the body and can be expressed in high concentrations. This stability is important for the molecule's function as a drug target, as it allows it to remain in the body long enough to interact with the target protein.
The structure of miRNA-7110 is also unique. It has a head composed of 19 amino acid residues and a tail composed of 11 amino acid residues. The head contains a unique feature called a double-stranded loop, which is a common structural motif in miRNA molecules. The double-stranded loop is composed of the amino acids Asp-22 and Asn-23, and it plays a critical role in the stability and function of the molecule.
In addition to its unique structure, miRNA-7110 has also been shown to have unique functions. For example, studies have shown that miRNA-7110 can act as a negative regulator of gene expression, which means that it can reduce the amount of a particular protein produced in the cell. This can be an important drug target in diseases where too much of a particular protein is produced, such as cancer.
Another function of miRNA-7110 is its potential as a biomarker. The molecule has been shown to be downregulated in a variety of cancer types, which makes it a potential target for cancer diagnostics and therapies. For example, studies have shown that miRNA-7110 is downregulated in human breast cancer cells, which makes it a potential target for breast cancer treatments.
In addition to its potential as a drug target and biomarker, miRNA-7110 is also of interest to researchers as a potential therapeutic agent. Studies have shown that miRNA-7110 can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that miRNA-7110 can be used to treat cancer by inhibiting the production of a particular protein that is involved in cancer growth and spread.
Overall, miRNA-7110 is a unique and promising molecule that has the potential to be a drug target and biomarker for a variety of diseases. Its stability, structure, and functions make it an attractive target for researchers to study and develop new treatments. As research continues to advance, it is likely that the role of miRNA-7110 in disease will become increasingly important and its potential as a therapeutic agent will be further explored.
Protein Name: MicroRNA 7110
The "MIR7110 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR7110 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR7111 | MIR7112 | MIR7113 | MIR7114 | MIR7150 | MIR7151 | MIR7152 | MIR7153 | MIR7154 | MIR7155 | MIR7156 | MIR7158 | MIR7159 | MIR7160 | MIR7161 | MIR7162 | MIR718 | MIR720 | MIR744 | MIR7515 | MIR758 | MIR759 | MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920
